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ABSTRACT
INTRODUCTION: The role of melatonin in hemostasis is still poorly studied.
PURPOSE: The purpose of this study was to investigate the effects of melatonin and luzindole, inhibitor of 




, on plasma levels of tissue factor, tissue factor pathway inhibitor and 
von Willebrand factor.
MATERIAL AND METHODS: The study was performed on 52 male Wistar rats, kept at 12/12 h natural reg-
imen dark/light. The daily doses of melatonin 0.2 mg/kg b.m. and luzindole 0.4 mg/kg b.m. were applied 
subcutaneously twice daily at intervals of 12h for three consecutive days. The rats were distributed into 
four equal groups (n=13) and were treated as follows: the first group (control group) – by saline; the second 
group – by melatonin; the third group – by luzindole; and the fourth group – by luzindole and an hour lat-
er by melatonin.
RESULTS: The results show that melatonin significantly increases the plasma levels of TF, reduces the val-
ues of free TFPI antigen and free TFPI activity, and increases the values of vWF antigen and vWF activity. 
Applied alone, luzindole lowers the plasma levels of TF, increases the values of free TFPI antigen and free 
TFPI activity; decreases the values of vWF antigen and vWF activity. Pretreatment with luzindole repeats 
the effect of self-administration. The received data show that melatonin induces a pronounced tendency to 
hypercoagulability in rats by a significant increase in TF, a decrease of free TFPI and free TFPI activity, as 
well as an increase in vWF antigen and vWF activity.





 receptors for accomplishing the effects of the hormone.






Tissue factor (TF), also known as plasma fac-
tor III, is a transmembrane glycoprotein which plays 
an initiating role for blood coagulation in the extrin-
sic pathway (1,2). It is widely present in all tissues but 
is expressed mostly in subendothelial cells, adventi-
tial fibroblasts, alveolar cells, cardiomyocytes, astro-
cytes, trophoblasts, and others (3,4,5). The tissue fac-
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tor has a high affinity to the VIIa factor and togeth-
er they form the TF/FVIIa complex (tenase complex), 
which activates IX and X factors, and thus, the coag-
ulation cascade to form fibrin (6,7).
The tissue factor pathway inhibitor (TFPI) is a 
major physiological regulator of the TF-induced co-
agulation (8,9). Its biosynthesis is associated primar-
ily with the microvascular endothelium (10,11). The 
TFPI molecule contains three consecutive Kunitz-
type protease inhibitor domains, and the second do-
main (K2) connects and inhibits the Xa factor, and 
the first (K1) – with the tenase complex (TF/FVI-
Ia) (12,13). As a result of this, a quaternary complex 
TFPI – TF/FVIIa – FXa is formed, which is inactive 
(14). This complex is the basis of the regulatory effect 
of TFPI on the initiated by the TF intrinsic pathway 
for thrombin generation (1,15).
The Von Willebrand factor (vWF) is a glycopro-
tein, which performs two key functions in normal he-
mostasis. The first – mediates the adhesion of plate-
lets to the subendothelial matrix after vascular injury 
(16,17) and the second – protects the VIII factor from 
proteolytic degradation (18). vWF is released into cir-
culation by secretion from endothelial cells (accumu-
lates in Weibel-Palade bodies) and platelets (their al-
pha granules) (19,20). It is well known that abnor-
malities in platelet plug and fibrin formation are ob-
served in patients with von Willebrand disease (17).
PURPOSE 
The purpose of this study was to investigate the 
effect of melatonin and luzindole (melatonin recep-
tors inhibitor – type 1 and 2) on plasma levels of tis-
sue factor, tissue factor pathway inhibitor and von 
Willebrand factor.
MATERIAL AND METHODS 
Experiments were carried out on 52 white male 
Wistar rats, weighing 200–220 g, kept at natural reg-
imen dark/light 12/12 h in accordance with Europe-
an Convention and Directives (Protection of animals 
used for experimental purposes, Council Directive 
86/609/EEc of November 1986, Directive 2010/63/
EU of the European Parliament and of the Council 
of September 2010). Rats were fed by standard food 
and water ad libitum. The daily doses of melatonin 
(Merck, Germany) 0.2 mg/kg b.m., and luzindole 
(Sigma Chemicals, USA) – 0.4 mg/kg b.m. were ap-
plied s.c. twice daily at intervals of 12h, for three con-
secutive days. The upper doses were determined ex-
perimentally in preliminary studies and according 
to literature data. The rats were distributed into four 
equal groups (n=13) and were treated as follows: the 
first group (C) (control group) – by saline; the second 
group – by melatonin (M); the third group – by luz-
indole (L); and the fourth group – by luzindole and 
an hour later by melatonin (L+M). 
The necessary blood volume from a rat was re-
ceived by cardiac puncture under urethane  narco-
sis in single usage plastic tubes, using sodium citrate 
0.11 mol/l (blood citrate ratio 9:1) as anticoagulant. 
TF was determined by an American Diagnos-
tica, inc. test (USA), and by performing Diagnostica 
Stago tests (France), the following were determined: 
free TFPI, free TFPI activity, vWF antigen (vWF:Ag) 
and vWF activity, defined by collagen binding capac-
ity (vWF:CB capacity).
Rats were autopsied and examined for macro-
scopic haemorrhages. Preparations from internal or-
gans were stained by hematoxylin-eosin and for fi-
brin by Weigert, and inspected for microhaemor-
rhages and intravascular coagulation.
STATISTICAL ANALYSIS 
Data were processed by variation analysis using 
Student–Fisher’s t-test on GrafpadPRYSM 4.2 soft-
ware. Values of p< 0.05 were considered significant.
RESULTS 
Results are presented in Fig. 1–5. Fig. 1 shows 
that melatonin increases plasma levels of TF (pg/ml) 
from 120.30±6.29 to 159.80±10.42, (p<0.01). Luz-
indole self-administration and luzindole pretreat-
ment with a subsequent injection of melatonin, de-
creases the values  of TF to 42.23±3.05 (p<0.001) and 
52.31±6.340 (p<0.001), respectively. Changes in plas-
ma levels of free TFPI (ng/ml) (Fig. 2), indicate that 
melatonin decreases its values from 11.87±0.54 in the 
control group – to 5.50±0.46 (p<0.001), luzindole in-
creases them to 15.48±1.06 (p<0.01), while pretreat-
ment with luzindole – to 16.03±0.85 (p<0.001). 
Melatonin reduces the free TFPI activity (Fig. 3) 
from 93.41±6.96 in controls – to 53.19±9.29 (p<0.01), 
luzindole  increases it to 146.50±11.05 (p<0.001), as 
does the pretreatment with luzindole – to 153.40±9.31 
(p<0.001). 
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Plasma levels of vWF antigen (Fig. 4) un-
der the influence of melatonin are highly elevat-
ed (122.50±6.63, p<0.001) compared to the control 
group rats (82.01±6.42). Treatment with luzindole 
was followed by a reduction of vWF antigen levels to 
49.01±4.05 (p<0.001). Strong reduction was also ob-
served after pretreatment with luzindole (41.10±3.41, 
p<0.001). 
The vWF activity increases under the influence 
of melatonin to 167.70±9.65 (p<0.01) (Fig. 5), rela-
tive to controls (127.10±5.79). Luzindole reduces the 
activity to 68.91±5.15 (p<0.001), while pretreatment 
with luzindol – down to 60.54±3.04 (p<0.001).
DISCUSSION
Fig. 1 shows that melatonin, administered to 
the rats, causes a significant increase in plasma lev-
els of TF (p<0.01) compared to the control group. 
Since TF is known primarily as a trigger of the ex-
trinsic coagulation pathway and thrombogenesis in a 
Fig. 2. Effects of melatonin (0.2 mg/kg b.w.) and luzindole 
(0.4 mg/kg b.w.), applied s.c. to male Wistar twice daily at 
intervals of 12h, for three consecutive days on free TFPI 
(ng/ml). Free TFPI – free Tissue factor pathway inhibitor; 
C – control group, injected by saline; M – melatonin; L – 
luzindol; L+M – luzindol followed after 1 h by melatonin 
*** p < 0.001; ** p < 0.01
Fig. 3. Effects of melatonin (0.2 mg/kg b.w.) and luzindole 
(0.4 mg/kg b.w.), applied s.c. to male Wistar twice daily 
at intervals of 12h, for three consecutive days on activity 
free TFPI (%). Free TFPI:Аct – free Tissue factor pathway 
inhibitor activity; C – control group, injected by saline; M 
– melatonin; L – luzindol; L+M – luzindol followed after 
1 h by melatonin
*** p < 0.001; ** p < 0.01
Fig. 4. Effects of melatonin (0.2 mg/kg b.w.) and luzindole 
(0.4 mg/kg b.w.), applied s.c. to male Wistar twice daily 
at intervals of 12h, for three consecutive days on VWF 
antigen (%). VWF:Ag – von Willebrand factor, antigen; 
C – control group, injected by saline; M – melatonin; L – 
luzindol; L+M – luzindol followed after 1 h by melatonin
*** p < 0.001
Fig. 1. Effects of melatonin (0.2 mg/kg b.w.) and luzindole 
(0.4 mg/kg b.w.), applied s.c. to male Wistar twice daily 
at intervals of 12h, for three consecutive days on TF level  
(pg/ml). TF – Tissue factor; C – control group, injected 
by saline; M – melatonin; L – luzindol; L+M – luzindol 
followed after 1 h by melatonin 
*** p < 0.001; ** p < 0.01
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number of diseases (1,2,21), it could be assumed that 
melatonin induces a tendency to hypercoagulability. 
This assumption is supported by our previous study 
(22) where it was shown that this hormone violates 
the equilibrium between the coagulant and antico-
agulant system in favor of the coagulant. The fore-
going analysis allows to assume that increased plas-
ma levels of TF under the influence of melatonin are 
a part of the mechanism explaining the tendency to 
hypercoagulability, which is convincingly shown in 
the already published article. Self-administration of 
luzindole strongly reduces the TF levels, (p<0.001), 
which gives grounds most likely to assume that 





moves to a large extent the effect of endogenous mel-
atonin on structures associated with the formation of 
this factor. We cannot exclude the fact, albeit hypo-
thetically, that luzindole may inhibit somewhat the 
biosynthesis and secretion of endogenous melatonin, 
which is relevant to the final effect. For now, there 
are no published data on the level of melatonin in 
plasma after administration of luzindole. Of partic-
ular interest are the results from the fourth group of 
animals, where melatonin is administered after pre-
treatment with luzindole. On the one hand, the re-
sults repeate those from the third group (luzindole 
only). On the other hand, it shows that blocking the 
melatonin receptors suppresses the effect of endoge-
nous and exogenous melatonin, i.e. these results are 
new evidence for the role of melatonin receptors as 
well as the importance of endogenous melatonin in 
TF formation.
The results presented in Fig. 2 and Fig. 3 are a 
logical continuation of those in Fig. 1, showing the 
changes in TFPI, also known as major physiological 
inhibitor of TF-mediated coagulation cascade (1,8,9). 
Based on this fact and the well-known mechanism 
of TFPI action (12-15) there is reason to assume that 
the significantly lower levels of free TFPI (Fig. 2) 
(p<0.001) and especially free TFPI activity (Fig. 3) 
(p<0.01) under the influence of melatonin, are inevi-
tably accompanied by development of a tendency to 
hypercoagulability. Applied alone, luzindole increas-
es significantly free TFPI (Fig. 2) (p<0.01), as well as its 






al effects. On the one hand, they mediate the effects 
of melatonin, and on the other – their blocking acti-
vates the formation of both the free form TFPI, and 
free TFPI with high activity. Our study does not al-
low to conclude whether blocking of these receptors 
initiates increased biosynthesis of TFPI, or changes 
only in the surveyed indicators – free TFPI and free 
TFPI activity. Pretreatment with luzindole almost 
entirely repeats the results from the third group (luz-
indole only) and is a new evidence that the effects of 
exogenous and endogenous melatonin are blocked, 
and also for the significance of its receptors on the 
plasma level of free TFPI and its activity.
The presented in Fig. 4 and Fig. 5 results show 
the effects of melatonin and luzindole on vWF, de-
fined as antigen and activity. The interpretation of 
these results would have been accurate in the light of 
the literature data which show that vWF, on the one 
hand, has a role in triggering normal hemostasis, and 
the other – the increase of its plasma level is to be re-
garded as a risk thrombogenic factor (16, 23). There-
fore, the significantly elevated vWF antigen level (Fig. 
4) (p<0.001) and its activity (Fig. 5) (p<0.01) found in 
this case, is accepted as a fact, which allows to say that 
melatonin induces tendency to hypercoagulability in 
rats. No less important information give the results 
obtained from the group of rats injected with luz-





) induces a strong decrease of both 
the vWF antigen level (Fig. 4) (p<0.001), and vWF ac-
Fig. 5. Effects of melatonin (0.2 mg/kg b.w.) and luzindole 
(0.4 mg/kg b.w.), applied s.c. to male Wistar twice 
daily at intervals of 12h, for three consecutive days on 
activity vWF:CB (%). vWF:CB capacity – activity vWF as 
estimated by collagen binding capacity; C – control group, 
injected by saline; M – melatonin; L – luzindol; L+M – 
luzindol followed after 1 h by melatonin
*** p < 0.001; ** p < 0.01
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tivity (Fig. 5) (p<0.001). We believe that the signifi-
cantly reduced values  were primarily the result of the 
inability of endogenous melatonin to achieve its stim-
ulating effects on the formation of vWF and its acti-
vation. From the application of luzindole followed by 
melatonin (the fourth group of rats) can be conclud-
ed that in essence it is not different from the just men-
tioned results, i.e. the third group (luzindole only). 
It is imperative to add that in this case, the blocking 
of melatonin receptors blocks the effects of both en-
dogenous and exogenous melatonin, which may ex-
plain the significantly lower values  of vWF:Ag (Fig. 4) 
(p<0.001) and vWF:Act (Fig. 5) (p<0.001) than those 
of the control group. It is seen that melatonin is an 
important regulator of the whole chain – from the 
biosynthesis of vWF to the formation of high activ-
ity vWF.
These results not only confirm the established 
in our previous studies effect of melatonin on he-
mostasis, namely – a tendency to hypercoagulability 
(22,24,25), but also indicate that this hormone causes 
significant changes in TF, TFPI and vWF, which are 
the basis of this trend.
CONCLUSION
The results of our study allow us to summarize 
that the pineal hormone melatonin induces a pro-
nounced tendency to hypercoagulability in rats by 
a significant increase of TF, decrease in plasma lev-
els of free TFPI and free TFPI activity, as well as by 
an increase in vWF antigen  and vWF activity. Luz-
indole self-administration and luzindole pretreat-





ceptors for accomplishing the effects of the hormone.
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